Healthcare Services

Global Genomic Biomarkers Market Set for Strong Expansion Reaching $19.32 Billion by 2030 at 17.2% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Genomic Biomarkers Market Across 2026–2030?

The genomic biomarkers market has seen rapid expansion in recent years. Its valuation is anticipated to rise from $8.72 billion in 2025 to $10.24 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.5%. The expansion observed historically is largely due to progress in genomic sequencing technologies, a surge in oncology-focused biomarker research, the wider acceptance of personalized treatment methods, refinements in clinical validation structures, and the increasing availability of genomic databases.

The genomic biomarkers market is poised for significant expansion in the coming years, with its valuation projected to reach $19.33 billion by 2030, driven by a robust compound annual growth rate (CAGR) of 17.2%. This anticipated growth stems from several factors, including heightened investments in precision medicine initiatives, a greater need for early disease identification tools, the broadening scope of biomarker-guided drug development, the increasing incorporation of AI in biomarker analysis, and strengthened regulatory backing for individualized treatments. Key developments expected during this period involve a greater embrace of biomarker-informed precision medicine, the escalating integration of genomic data into clinical decision-making processes, the expanded application of companion diagnostics, the proliferation of multi-omics biomarker platforms, and a sharper emphasis on standards for clinical validation.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19485&type=smp

What Primary Drivers Are Shaping The Development Of The Genomic Biomarkers Market?

The genomic biomarkers market is anticipated to expand due to the rising demand for personalized medicine. Personalized medicine, also known as precision medicine, is a medical strategy that customizes healthcare choices and therapies for each patient’s specific traits, mainly using their genetic and genomic data. This growing need for personalized medicine stems from factors like a greater focus on patient-centered care, advancements in genetic sequencing and analysis, a patient-centric methodology, and the utilization of EHRs for data storage and analysis. Genomic biomarkers are vital in personalized medicine, allowing healthcare providers to adapt medical treatments to an individual’s distinct genetic profile. This methodology, also referred to as precision medicine, seeks to enhance treatment efficacy and reduce adverse effects by accounting for genetic variations among individuals. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported in February 2024 that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the expanding demand for personalized medicine propels the growth of the genomic biomarkers market.

What Segmentation Levels Are Considered In The Genomic Biomarkers Market?

The genomic biomarkers market covered in this report is segmented –

1) By Type: Predictive Biomarkers, Prognostic Biomarkers

2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications

3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility

4) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Subsegments:

1) By Predictive Biomarkers: Drug Response Biomarkers, Companion Diagnostics Biomarkers, Pharmacodynamic Biomarkers, Predictive Genetic Markers for Disease Susceptibility

2) By Prognostic Biomarkers: Cancer Prognostic Biomarkers, Cardiovascular Disease Prognostic Biomarkers, Neurodegenerative Disease Prognostic Biomarkers, Infectious Disease Prognostic Biomarkers

Which Trends Are Influencing The Genomic Biomarkers Market?

Major companies operating in the genomic biomarkers market are focused on developing innovative products, such as lung reagents, to enhance the detection of specific genetic mutations in lung cancer, improve diagnostic accuracy, and facilitate personalized treatment approaches by leveraging advanced genomic technologies. Lung reagents refer to specialized chemical or biological substances used in diagnostic tests, research, or medical procedures related to the lungs, helping in precision medicine by guiding treatment choices based on the specific genetic profile of the cancer. For instance, in December 2023, Biofidelity, a UK-based company specializing in developing advanced genomic assays and precision diagnostics, launched ASPYRE-Lung reagents. The ASPYRE-Lung reagents are designed to identify key genetic mutations and alterations in lung cancer, which are critical for guiding targeted therapies and personalized treatment strategies.

Which Leading Firms Are Contributing To The Growth Of The Genomic Biomarkers Market?

Major companies operating in the genomic biomarkers market are Thermo Fisher Scientific Inc., Roche Diagnostics International Ltd., Illumina Inc., PerkinElmer Inc., Almac Group, Azenta Inc., Novogene Corporation, Oxford Nanopore Technologies Ltd., Celerion, Quanterix Corporation, Bio-Rad Laboratories Inc., NantHealth Inc., Centogene N.V., Sophia Genetics SA, Envisagenics, Deep Genomics, Creative Diagnostics, Macrogen Inc., Guardant Health Inc., Sema4

Read the full genomic biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/genomic-biomarkers-global-market-report

How Does The Genomic Biomarkers Market Perform Across Major Global Regions?

North America was the largest region in the genomic biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Genomic Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19485&type=smp

Browse Through More Reports Similar to the Global Genomic Biomarkers Market 2026, By The Business Research Company

Genomics Global Market Report

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Genomics Personalized Health Global Market Report

https://www.thebusinessresearchcompany.com/report/genomics-personalized-health-global-market-report

Consumer Genomics Global Market Report

https://www.thebusinessresearchcompany.com/report/consumer-genomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795